Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective Activity.
Litvin AA, Kolyvanov GB, Bochkov PO, Shevchenko RV, Podol'ko AL, Kolyasnikova KN, Zherdev VP · 2022 · Bulletin of experimental biology and medicine
What does this source report?
GZK-111 underwent extensive conversion to CPG in rats. CPG persisted more than twice as long in plasma and reached higher concentrations than the parent compound.
- Population and setting
- Rats; intravenous and intragastric pharmacokinetics
- Evidence type
- Animal / experimental
- Preparation
- See the original report; formulation details require verification.
- Source language
- English indexed abstract; original language: eng
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Abstract reviewed
Source access and review scope
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Recorded source-check date: 2026-10-05. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Litvin AA, Kolyvanov GB, Bochkov PO, Shevchenko RV, Podol'ko AL, Kolyasnikova KN, Zherdev VP. Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective Activity. Bulletin of experimental biology and medicine 2022.
Molekul research summary: https://molekul.io/research/rp-35006488. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry